TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hearing sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Removal of p‐cresol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Removal of beta2‐microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of the cyst-like component from subchondral BMLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STV associated with knee symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptor expression changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain intensity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in saturated fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve (AUC(0-48)) for serum exogenous calcitriol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (C(max)) for serum exogenous calcitriol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle endurance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dorsiflexor control during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language development improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Motor development improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: risk of combined outcome event
Endpoint domain: Mortality/survival
Primary endpoint: Fractional Shortening (FS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Atrial (LA) and Left Ventricular (LV) diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Exhaled H2S concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in functional threshold (FT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean deviation (MD) in central visual field sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: play performance generalisation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Patient information recall test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Heart failure symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thirst symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of industry-sponsored gifts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Perception of bias from industry interactions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Belief in valuable education from industry interactions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prediction of implantability of hearing devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma brain natriuretic peptide (BNP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QALY difference between groups
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta‐glucuronidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in connectivity pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median limb fat changes (g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: triglycerides (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total cholesterol (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean triazolam AUC(0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain scores during and after lithotripsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of RNA-based test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of RNA-based test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ocular chlamydia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal decrease in haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skills performance in following emergency procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotion Identification and Discrimination (EMOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BLS-AED action skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate in non-small-cell lung cancer patients
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3-4 toxicity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Survival for mesothelioma patients
Endpoint domain: Mortality/survival
Primary endpoint: ad libitum food intake at 120 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in errors in defibrillation doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative defibrillation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: oral malodor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in alertness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ratio of AUC(0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ratio of AUC(0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ratio of C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preterm birth and/or low birth weight
Endpoint domain: Mortality/survival
Primary endpoint: action myoclonus improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: myoclonus-related functional disability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: dystonia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete apical closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS values with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Defect (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Sensitivity (MS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean PASI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PDI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cumulative UVB dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coefficient of fat absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of burn pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of burn pain hot sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ESA (Emotional Support Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiplicity of infection (MOI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total service costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for homologous transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean hemoglobin concentration at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pelvic recurrences
Endpoint domain: Adverse events/effects
Primary endpoint: therapy attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: completion rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: stone retropulsion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaphylaxis occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Severe reactions (grade 3/4)
Endpoint domain: Adverse events/effects
Primary endpoint: onset time to the T(10) dermatome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of the sensory block at T(10) dermatome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of the motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in guideline concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cannabis-related knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in triglyceride/HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Reduced LV compliance (EDV20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV remodeling (increased RV wall thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Return to work within 60 days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: withdrawal-related disruptions in sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: withdrawal-related disruptions in mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: withdrawal-related disruptions in food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Autonomic arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of alerting and orienting attention network function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Phosphate removal during HD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bacterial colony-forming unit reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of immune thrombocytopenia (IT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: itch intensity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60-minute patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: >70% ST-segment resolution at 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain intensity suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Case scheduling concerns
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Evening PEFR (% predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response (iOR)
Endpoint domain: Physiological/clinical
Primary endpoint: Optimal response rate to imatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight-for-age z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory Organization Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turn time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Turn sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the BAS global subscale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HBV DNA negative conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative gene-resistant rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of renal impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to first response in terms of new hair growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SALT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of echocardiographic responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical response (6-minute walking test improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consumption of propofol and sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate for AP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capacity of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma TXB2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of analgesic doses consumed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum testosterone (TT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in median eCO from baseline to follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in plasma choline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimum postoperative creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of oliguria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: adverse events of the renal system
Endpoint domain: Adverse events/effects
Primary endpoint: Pass rate for grader pairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative alfentanil requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agility performance level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of worsening renal function (WRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Admission to hospital for cardiovascular reasons
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: remission at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unstable walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slowness of walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prolongation of the double-support period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of OSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Seroprotective immune response for diphtheria, tetanus and hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti pertussis antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events (pain at injection site, mild fever, transient crying)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression status at 9 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feeling better informed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Platelet Reactivity (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge, awareness, and confidence regarding self-examination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in PCL scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant change (response) rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EDSS score progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSIS-29phys score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score in 28 joints (DAS28-CRP) at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Disease Activity Index (CDAI) at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of advanced gastric lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in cognitive development and behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: middle cerebral velocity (MCAvmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: cardiac output (Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systemic vascular resistance (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Flow-mediated vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plasma 8‐iso prostaglandin F2α (8‐iso‐PGF2a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement functions improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical osteoporotic fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fracture incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cough bouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cough components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cough effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in mental health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physical health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric lumbar extension muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal dietary intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health perception (SF-36 dimension 'health change')
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30-day frequency of malt liquor use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day quantity of malt liquor use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of cigarette and marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IM recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life (QOL) as measured by diary
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Night time awakenings
Endpoint domain: Adverse events/effects
Primary endpoint: Cost per DALY averted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of patients on sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes